OTC cannabidiol set to open $200m market – but is there evidence to back it up?

A picture of a marijuana leaf lying on top of a cardboard box
The decision means consumers will have easier access to cannabidol products. Image: Unsplash
The Australian Therapeutic Goods Administration’s (TGA) landmark interim decision to make registered low-dose cannabidiol (CBD) products available in pharmacies could open up a market worth more than $200 million, according to a Q3 report by medicinal cannabis experts Fresh Leaf Analytics.  The proposed new regulations mean that companies could apply for Schedule 3 (S3) or “over the counter” registration for oral or oromucosal CBD products such as oils, capsules, sprays and wafers, as ear

This content is for IR Pro subscribers only.

Subscribe now to unlock an all-access pass.

IR Pro - monthly

$5 +GST for the first 30 days. (Auto renews at $28+GST per month.)
  • Unlimited news access
  • Exclusive members only masterclasses (live and on-demand)
  • Weekly careers advice
  • Weekly and quarterly digital magazines delivered to your inbox
Subscribe now
MOST POPULAR

IR Pro - annual

$312 +GST per year. (Auto renews annually.)
  • Unlimited news access
  • Exclusive members only masterclasses (live and on-demand)
  • Weekly careers advice
  • Weekly and quarterly digital magazines delivered to your inbox
Subscribe now